California-based PowerVision raises plans to spend its new funds completing a CE Mark study and launching a U.S. clinical trial for its FluidVision intraocular lens.
Ophthalmic devices maker PowerVision finally put a ribbon on its $30 million Series D funding round, planning on using the funds to advance clinical trials in support of regulatory approvals in Europe and the U.S.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1pC1yig
Cap comentari:
Publica un comentari a l'entrada